Top Manchester Pharmaceutical Companies (7)
Don't see your company?
Create a company profile
Blueberry Therapeutics Ltd. is a modern drug discovery and development company which puts people first whether patients, employees, investors or partners. We have created an open, imaginative and fun team environment with a very serious objective: to create new, safer and more effective medicines to treat human disease and make patients feel better. Blueberry focuses on the research and development of treatments for skin diseases. We do this by employing state of the art preclinical research technologies to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic. In the clinic, Blueberry uses smart, agile, clinical designs to deliver high quality trials more rapidly and with reduced development costs. Blueberry will rapidly progress new therapies to clinical proof-of-concepts and beyond with appropriate, effective and safe doses with full regulatory and ethical approval. We have programs addressing Onychomycosis, Tinea Pedis, Acne and Atopic Dermatitis.
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim is in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis and scedosporiosis (including lomentosporiosis). Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA. F2G is headquartered in the UK with subsidiaries in the US and Austria.
At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets.
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the complex and rapidly changing healthcare ecosystem. Together, our experts help clients connect patients with life-changing therapies, realizing the potential of strategies and solutions to accelerate innovation that improves lives.
For over a decade, we have been recognised as the leading experts in decentralising clinical trial delivery, prioritising patient care to enhance patient experiences and improve safety. We take the pressure off with our advanced technology and services that support the planning, execution, and analysis of clinical trials, ensuring trials are conducted efficiently to build real-world evidence grounded upon structured, accurate data.
Biorelate helps scientists solving the most difficult biomedical challenges of today. We do this by providing the most novel knowledge graph in biopharma for better knowledge review, target and biomarker discovery, mechanism of action understanding, and indication expansion
Helios Medical Communications is a full-service, independent, global healthcare communications and strategic consultancy agency. We specialise in delivering high-quality, high-impact bespoke solutions to meet our clients’ needs. Our core services include: · Strategic medical communications consultancy · Medical education · Publications and medical writing · External expert strategy and collaboration · Internal training solutions (MSL and brand) · Meetings · Multichannel communications · Patient-centric communications · Creative branding and design Our Core Values People Our people are our greatest asset. Our team is highly experienced, enthusiastic and committed to delivering the highest possible standards. Perspective We design and implement bespoke creative and intelligent solutions, drawn from our many years of experience, to help our clients reach their goals. Passion We are passionate about what we do. We bring energy to each project, and have a proactive, ‘can do’ attitude. Partnership To deliver the best results for our clients, we believe that developing long-term partnerships, built on a foundation of trust, respect and integrity, is key.
Work Your Passion. Live Your Purpose.
